Roivant Sciences financials
$36.50−1.30%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jun 30 | Q4 '26 Mar 31 | Q3 '26 Dec 31 | Q2 '26 Sep 30 | Q1 '26 Jun 30 | Q4 '25 Mar 31 | Q3 '25 Dec 31 | Q2 '25 Sep 30 | Q1 '25 Jun 30 | Q4 '24 Mar 31 | Q3 '24 Dec 31 | Q2 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $2.5M | $2.0M | $1.6M | $2.2M | $7.6M | $9.0M | $4.5M | $8.0M | $9.0M | $15.6M | $3.6M |
| Gross profit | $1.4M | $2.5M | $2.0M | $1.6M | $2.2M | $7.6M | $9.0M | $4.5M | $8.0M | $10.4M | $15.4M | $3.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 115.6% | 98.7% | 100.0% |
| Operating income | -$366.0M | $415.2M | -$339.2M | -$306.2M | -$284.9M | -$285.0M | -$274.4M | -$341.7M | -$212.6M | -$224.2M | -$221.0M | -$196.5M |
| Net income | -$189.8M | $303.0M | -$265.9M | -$113.5M | -$223.4M | -$206.5M | $169.4M | -$230.2M | $95.3M | -$151.1M | $5.10B | -$304.3M |
| Net margin | −13164.8% | 12023.6% | −13301.2% | −7225.9% | −10292.9% | −2727.5% | 1878.3% | −5143.8% | 1192.7% | −1675.3% | 32747.6% | −8342.3% |
| Diluted EPS | $-0.26 | $0.42 | $-0.38 | $-0.17 | $-0.33 | $-0.31 | $0.23 | $-0.31 | $0.12 | $-0.16 | $6.03 | $-0.40 |
| EBITDA | -$365.8M | -$354.4M | -$338.5M | -$305.3M | -$283.8M | -$283.5M | -$271.5M | -$336.9M | -$207.7M | -$206.8M | -$215.6M | -$208.3M |
| Operating cash flow | -$270.5M | -$163.8M | -$196.5M | -$185.7M | -$204.4M | -$172.6M | -$207.3M | -$266.8M | -$192.8M | -$108.5M | -$210.5M | -$196.4M |
| Free cash flow | -$270.9M | -$165.1M | -$201.4M | -$193.5M | -$208.4M | -$173.4M | -$209.1M | -$267.8M | -$193.8M | -$108.8M | -$210.8M | -$196.7M |
| Diluted shares | 720.8M | 717.4M | 696.9M | 680.9M | 680.3M | 661.8M | 722.7M | 735.5M | 781.6M | 950.2M | 844.5M | 770.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.25B | $1.42B | $1.48B | $1.24B | $1.24B | $2.72B |
| Short-term investments | $2.59B | $2.87B | $3.05B | $3.15B | $3.26B | $2.17B |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $5.31B | $5.71B | $5.23B | $5.06B | $5.03B | $5.44B |
| Total liabilities | $384.6M | $416.3M | $251.1M | $257.1M | $216.7M | $249.7M |
| Shareholders' equity | $4.92B | $5.29B | $4.97B | $4.81B | $4.82B | $5.19B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology